VVARDIS Secures $35 Million from OrbiMed for Curodont Expansion

vVARDIS AG, a Swiss dental company known for innovative solutions, announced a $35 million financing partnership with OrbiMed, a global healthcare investor. This investment aims to fuel vVARDIS's growth and global expansion of Curodont, a drill-free treatment for early tooth decay. Curodont addresses a critical health issue, as tooth decay is the world's most prevalent disease, according to the World Health Organization.

The expansion is timely, with dental care shifting towards non-invasive treatments. Curodont allows dental professionals to treat decay in 5 to 10 minutes efficiently. The collaboration with OrbiMed aligns with vVARDIS's strategy to establish itself as a leader in dental innovation, leveraging proprietary formulas and comprehensive research.

With over 300,000 successful treatments in 2024 and recognition from U.S. and European universities, vVARDIS is poised to redefine dental care standards. The financing will enhance their capacity to serve both dental professionals and patients globally, aiming for a pain-free, accessible treatment option for early decay.